Abstract:The treatment of multidrug-resistant Gram-negative bacteria (MDR-GNB) infections in critically ill patients presents many challenges. Since an effective treatment should be administered as soon as possible, resistance to many antimicrobial classes almost invariably reduces the probability of adequate empirical coverage, with possible unfavorable consequences. In this light, readily available patient's medical history and updated information about the local microbiological epidemiology remain critical for defining the baseline risk of MDR-GNB infections and firmly guiding empirical treatment choices, with the aim of avoiding both undertreatment and overtreatment. Rapid diagnostics and efficient laboratory workflows are also of paramount importance both for anticipating diagnosis and for rapidly narrowing the antimicrobial spectrum, with de-escalation purposes and in line with antimicrobial stewardship principles. Carbapenem-resistant Enterobacteriaceae, Pseudomonas aeruginosa, and Acinetobacter baumannii are being reported with increasing frequencies worldwide, although with important variability across regions, hospitals and even single wards. In the past few years, new treatment options, such as ceftazidime/avibactam, meropenem/vaborbactam, ceftolozane/tazobactam, plazomicin, and eravacycline have become available, and others will become soon, which have provided some much-awaited resources for effectively counteracting severe infections due to these organisms. However, their optimal use should be guaranteed in the long term, for delaying as much as possible the emergence and diffusion of resistance to novel agents. Despite important progresses, pharmacokinetic/pharmacodynamic optimization of dosages and treatment duration in critically ill patients has still some areas of uncertainty requiring further study, that should take into account also resistance selection as a major endpoint. Treatment of severe MDR-GNB infections in critically ill patients in the near future will require an expert and complex clinical reasoning, of course taking into account the peculiar characteristics of the target population, but also the need for adequate empirical coverage and the more and more specific enzyme-level activity of novel antimicrobials with respect to the different resistance mechanisms of MDR-GNB.

Update on New Research in Gram-negative Infections European Congress of Clinical Microbiology and Infectious Diseases 2017 (22–25 April, Vienna, Austria)

Improving Outcomes in the Management of Gram-negative Bacterial Infections in the Face of Growing Antimicrobial Resistance.

Update on Clostridium Difficile from the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Vienna, Austria, April 22-25, 2017.

Treatment of Infections Due to MDR Gram-Negative Bacteria

New Antimicrobials for Gram-Positive Sustained Infections: A Comprehensive Guide for Clinicians

Current viewpoint on the epidemiology of nonfermenting Gram-negative bacterial strains

Treatment of infections caused by multidrug-resistant Gram-negative bacilli: a practical approach by the Italian (SIMIT) and French (SPILF) Societies of Infectious Diseases

Infections Caused by Resistant Gram-Negative Bacteria: Epidemiology and Management

Resistance, Current Treatments, and Future Innovations

The “Old” and the “New” Antibiotics for MDR Gram-Negative Pathogens: For Whom, When, and How

New perspectives in the antibiotic treatment of mechanically ventilated patients with infections from Gram-negatives

The past, present and future of polymicrobial infection research: Modelling, eavesdropping, terraforming and other stories

Priorities and Progress in Gram-negative Bacterial Infection Research by the Antibacterial Resistance Leadership Group

Safety evaluation of current therapies for high-risk severely ill patients with carbapenem-resistant infections

Update on the Epidemiology of Macrolide-Resistant Mycoplasma pneumoniae in Europe: A Systematic Review

Microbiological, Clinical, and PK/PD Features of the New Anti-Gram-Negative Antibiotics: β-Lactam/β-Lactamase Inhibitors in Combination and Cefiderocol—An All-Inclusive Guide for Clinicians

Treatment of Extensively Drug-Resistant Gram-negative Infections in Critically Ill Patients: Outcome of a Consensus Meeting at the 13th Asia-Pacific Congress of Clinical Microbiology and Infection, October 2012

Predicting early appropriate therapy for patients infected by carbapenem-resistant Gram-negative pathogens in intensive care units in Italy

Insights into the Rising Threat of Carbapenem-Resistant Enterobacterales and Pseudomonas aeruginosa Epidemic Infections in Eastern Europe: A Systematic Literature Review

New Antibiotics for Multidrug-Resistant Bacterial Strains: Latest Research Developments and Future Perspectives

Clinical Epidemiology of the Global Expansion of Klebsiella Pneumoniae Carbapenemases